Collaboration Delivers Personalized Diabetes Care
PALO ALTO, Calif., April 11, 2023 /PRNewswire/ -- Glooko, Inc. today announced a new global collaboration with Hedia. With this collaboration, it integrates its technology into Glooko's diabetes management platform for healthcare professionals and people with diabetes. This collaboration will create an interoperable solution that brings together connected care, remote patient monitoring and digital therapy technologies to improve access for people with type 1 and type 2 diabetes who require bolus insulin advice.
With Glooko's platform, patients can now share their diabetes data with their healthcare professionals, including blood glucose readings, insulin dose, food and carbohydrates, physical activity, blood pressure and weight. With the integration of Hedia Diabetes Assistant, people with diabetes will be able to receive bolus insulin dosing advice, providing personalized care and eliminating the need to manually calculate required insulin doses. Additionally, when used with connected insulin pens*, the integrated solution offers a high level of visibility to healthcare professionals treating multiple daily injections (MDI) patients. This integration enhances Glooko's remote patient monitoring capabilities and supports virtual consultations for MDI patients.
"We are extremely pleased with our collaboration with Hedia, which allows us to create this algorithm-driven innovation for personalized healthcare for diabetic patients and their healthcare teams," said Russ Johannesson, CEO of Glooko. "The reliable clinical data supporting the efficacy of Hedia demonstrate that this could be a viable alternative for patients who cannot access insulin pumps. This partnership demonstrates how interoperability offers people with diabetes the optimal tools to facilitate the control of your illness and improve your health, such as the stability of your blood glucose levels".
Peter Lucas, CEO of Hedia, says: "We are delighted that Glooko, a company with an extensive clinical network, is our partner in digital health. In addition to our strong clinical evidence, one of the key issues we consider when creating our technology is regulatory compliance and cybersecurity Glooko has proven its strength in these areas with various third party certifications and that is a key driver of our partnership Hedia's Class IIb Medical Device designation ensures that the better solutions to patients and their care teams."
The initial European launch of the integration is expected to take place in Q4 2023 and Q1 2024.
*The connected pen function is only available in the EU.
About GlookoGlooko improves health outcomes for people with chronic conditions through its connected, intelligent and personalized care platform. Our proven technologies improve people's lives by revolutionizing the connection between patients and providers, driving patient engagement and adherence through digital treatments, and accelerating the speed of clinical trials. Glooko works in more than 30 countries and in more than 8,000 clinics.
Glooko.com LinkedIn Twitter Instagram Facebook
About HediaHedia is a leading digital diabetes therapy company committed to helping people with insulin-dependent diabetes manage their disease. Making life easier for people with diabetes has been the driving force since the creation of Hedia Diabetes Assistant and the solution is available today in 11 countries. Based on the habits of the person with diabetes and personalized data, our diabetes app generates insulin recommendations from many aspects of diabetes management, such as recording blood glucose readings, monitoring active insulin, carbohydrate measurement, insulin dose calculation, activity tracking and recording of blood ketone levels.
Hedia.com LinkedIn
Press contactTanya RodanteDirector of Global Communicationspr@glooko.com
Logo - https://mma.prnewswire.com/media/1043398...
View original content: https://www.prnewswire.com/news-releases/glooko-anuncia-una-colaboracion-con-hedia-en-relacion-con-el-algoritmo-de-insulinizacion-301792778.html
